구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Main SC alternative to Columvi, with continuous rather than fixed duration.
기전. Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CD20 × CD3
Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
US, EU, JP
Approved
epkinly · epcoritamab · Epkinly · Tepkinly · GEN3013 · epcoritamab-bysp
2026-09-10
Data Confidence · High
Development Signal · Established
IgG1 bispecific antibody (DuoBody)
Controlled Fab-arm exchange with an inert Fc to avoid CD20-mediated effector crosslinking
Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers.
구조화 데이터
Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers.
CD20 antigen loss and exhausted effector T cells after multiple prior lines.
IgG1 bispecific antibody (DuoBody)
CD20 × CD3 · CD20 expression; ctDNA MRD investigational.
CRS mitigation during step-up; infection and neutropenia monitoring
Main SC alternative to Columvi, with continuous rather than fixed duration.
R/R DLBCL after ≥2 prior lines; R/R follicular lymphoma after ≥2 prior lines
3L+
Subcutaneous with step-up dosing
Weekly, then q2w, then q4w
DLBCL ORR ~61%; FL ORR ~82%
CRS mitigation during step-up; infection and neutropenia monitoring
Main SC alternative to Columvi, with continuous rather than fixed duration.
Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation.
Gradual T-cell activation due to slower subcutaneous absorption.
T-cell-mediated lysis of CD20+ lymphoma cells.
CD20 expression; ctDNA MRD investigational.
CD20 antigen loss and exhausted effector T cells after multiple prior lines.
구조화 데이터
rated consistent cytotoxic effects in B-cell lymphoma cell line-derived xenograft
Human, cynomolgus
~3 weeks at steady state
Peripheral B-cell depletion, cytokine kinetics, PET response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (R/R DLBCL)
APPROVAL · 2023년 5월
Follicular lymphoma indication
APPROVAL · 2024년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Main SC alternative to Columvi, with continuous rather than fixed duration.
기전. Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CD20 × CD3
Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
US, EU, JP
Approved
epkinly · epcoritamab · Epkinly · Tepkinly · GEN3013 · epcoritamab-bysp
2026-09-10
Data Confidence · High
Development Signal · Established
IgG1 bispecific antibody (DuoBody)
Controlled Fab-arm exchange with an inert Fc to avoid CD20-mediated effector crosslinking
Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers.
구조화 데이터
Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers.
CD20 antigen loss and exhausted effector T cells after multiple prior lines.
IgG1 bispecific antibody (DuoBody)
CD20 × CD3 · CD20 expression; ctDNA MRD investigational.
CRS mitigation during step-up; infection and neutropenia monitoring
Main SC alternative to Columvi, with continuous rather than fixed duration.
R/R DLBCL after ≥2 prior lines; R/R follicular lymphoma after ≥2 prior lines
3L+
Subcutaneous with step-up dosing
Weekly, then q2w, then q4w
DLBCL ORR ~61%; FL ORR ~82%
CRS mitigation during step-up; infection and neutropenia monitoring
Main SC alternative to Columvi, with continuous rather than fixed duration.
Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation.
Gradual T-cell activation due to slower subcutaneous absorption.
T-cell-mediated lysis of CD20+ lymphoma cells.
CD20 expression; ctDNA MRD investigational.
CD20 antigen loss and exhausted effector T cells after multiple prior lines.
구조화 데이터
rated consistent cytotoxic effects in B-cell lymphoma cell line-derived xenograft
Human, cynomolgus
~3 weeks at steady state
Peripheral B-cell depletion, cytokine kinetics, PET response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (R/R DLBCL)
APPROVAL · 2023년 5월
Follicular lymphoma indication
APPROVAL · 2024년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.